Three biotech stocks to buy now

Professional investors Ailsa Craig and Marek Poszepczynski of the International Biotechnology Trust pick three of their favourite biotech stocks to buy now.

Biotechnology investors are increasingly beginning to focus on life beyond the pandemic. There are many innovative companies in the biotech sector addressing long-term challenges, such as cancer and various neurological conditions. 

As we look forward to the eventual endemic stage of the pandemic, these companies will benefit from the resumption of standard medical activities. We could also see the development of groundbreaking new drugs to treat conditions with considerable unmet need. We highlight three portfolio holdings well placed to outperform. 

A niche with few competitors

Antipsychotic drugs are life-changing for patients, but the side effects can be severe. In certain cases patients develop treatment-induced tardive dyskinesia – involuntary movements similar to those experienced by patients suffering from Parkinson’s disease.

US biopharmaceutical company Neurocrine Biosciences (Nasdaq: NBIX) is working to tackle this problem. Ingrezza, one of its drugs, improves the quality of life for patients on antipsychotic medication, while Ongentys, another treatment, is used to treat Parkinson’s disease. During the pandemic, sales of these drugs slid sharply: movement disorders such as Parkinson’s tend to be diagnosed in person. The shares fell too, bringing their valuation down to a more attractive level. 

It will take time for sales trajectories to recover to pre-pandemic levels, but the long-term growth prospects for this company remain attractive. Neurocrine’s drugs address urgent, unmet medical needs, and few other competitors operate in the sector.

Making headway with headaches 

Migraines create debilitating auditory and visual disturbances as well as severe pain. Up to 25 million days of work and education are lost every year owing to migraines, according to The Migraine Trust. The condition also places significant strain on accident and emergency departments. However, after many years of research, a new treatment known as calcitonin gene-related peptide (CGRP) inhibition has proved effective. 

Injectable forms of this drug are already in use, but US-based Biohaven Pharmaceuticals (NYSE: BHVN) has developed it in a much more convenient tablet form. Biohaven recently received additional-usage approval for the treatment. It is applied to acute and chronic cases, as well as being used for migraine prevention. After the breakthrough, Biohaven announced a $1.2bn licensing deal with Pfizer for ex-US rights to the compound. This area has not seen major progress for many years, meaning competition is sparse.

Managers with a proven record

Cancer therapies have become more effective over the past decade, but treatment resistance remains a problem. US start-up ORIC Pharmaceuticals’ (Nasdaq: ORIC) principal drug, ORIC-101, targets the glucocorticoid receptor, which is linked to multiple types of treatment resistance.

Current trials are focused on prostate cancer, but if ORIC-101 proves effective, it could benefit sufferers of many other types of cancer. ORIC’s drugs are in the early stages of development, making it relatively risky. But it has a strong management team with a record of developing successful treatments, while the potential appetite for its products would be significant. 

Recommended

Cryptocurrency roundup: Putin backs crypto-mining, and spoof McDonald’s coin takes off
Bitcoin & crypto

Cryptocurrency roundup: Putin backs crypto-mining, and spoof McDonald’s coin takes off

Saloni Sardana looks at the cryptocurrency stories that caught our eye this week.
28 Jan 2022
Are recession fears justified? Maybe it’s time to look on the bright side
Economy

Are recession fears justified? Maybe it’s time to look on the bright side

There's a lot to feel nervous about right now, and many people are worrying about an impending recession. But it's by no means certain, says John Step…
28 Jan 2022
Making money is about to get much harder
Investment strategy

Making money is about to get much harder

Soaring inflation, geopolitical risk, bubbly stockmarkets - getting a return on your investment is going to get much more difficult – but not impossib…
28 Jan 2022
How to invest in the chipmakers fixing the semiconductor shortage
Share tips

How to invest in the chipmakers fixing the semiconductor shortage

Last year’s chip crunch brought home how dependent the world is on these tiny pieces of silicon. Chipmakers are rushing to build new factories. Will t…
28 Jan 2022

Most Popular

Amazon halts plans to ban UK Visa credit card payments
Personal finance

Amazon halts plans to ban UK Visa credit card payments

Amazon has said that it is to shelve its proposed ban on UK customers making payments with Visa credit cards.
17 Jan 2022
Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022